Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

CARLSBAD, Calif., Nov. 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.  Isis will develop both ISIS-GCGRRx and ISIS-GCCRRx to treat a broad population of diabetic patients.  The unique mechanism of action of these new drugs could allow each drug to be used in combination with other therapies for type 2 diabetes.

"Type 2 diabetes is a progressive disease.  More than half of all diabetic patients cannot reach acceptable glucose control with currently available therapies.  Our goal is to develop safe, effective drugs with unique mechanisms of action that can provide significant therapeutic benefit," said B. Lynne Parshall, Chief Operating Officer, Chief Financial Officer and Secretary of Isis. "This year we have made significant progress toward this goal.  Our ISIS-GCGRRx and ISIS-GCCRRx drugs are designed to reduce the activity of two critical hormones that oppose the action of insulin and cause increased glucose levels in diabetic patients.  The initial clinical development for both of these drugs will focus on treating diabetic patients with moderate to severe diabetes who cannot achieve adequate glucose control with existing treatments.  We believe that each drug could address a significant commercial market by providing long-term disease control in such patients."

ISIS-GCGRRx targets the glucagon receptor (GCGR) to reduce the effects of glucagon, a hormone that causes glucose production in the liver.  Reducing GCGR also increases the production of active glucagon-like peptide (GLP-1), a hormone that preserves pancreatic function and enhances insulin secretion. "Glucagon plays a particularly significant role in increasing blood glucose levels
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... and JERUSALEM , Feb. ... company developing octreotide capsules, its lead product for the ... $70 million Series E financing round. Participants in the ... Ventures, and an undisclosed blue chip public investment fund, ... 7 Med Health Ventures, Abingworth and ARCH Venture Partners. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law ... by time limits. They stated that in many cases, missing ... even nullify it. Many a time, delays in making an ... under BC law. As a result, experts at Jiwa Law ... consult a personal injury lawyer in order to know more ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... Cow Disease, also known as Bovine Spongiform Encephalopathy (BSE), affects ... control and the animal ultimately dies. Prion proteins are believed ... may contain these prion proteins and the disease might be ... drink its milk, according to a new study. ...
... has indicated the benefits of tomato and broccoli in the ... both the vegetables, are a great blessing in the reduction ... isolation. ,It is estimated that one out ... making it the most notorious of male cancers. Annually, 32,000 ...
... ‘present’ - the common cause of amnesia, also prevents victims ... in the present. ,Researchers, reporting their study ... Sciences at the Wellcome Trust Centre for Neuroimaging, University College ... the brain that is crucial in learning and memory. ...
... federal scanner, which has pointed out a 4% decline in ... Department of Health and Human Service has attributed this drop ... 1996 to 2003- to the spiraling growth in expenditures on ... ,The Agency for Healthcare Research and Quality in Health ...
... melanoma screening of adults age 50 or older appears ... screening programs, according to an article in the January ... only cancer for which incidence and death rates continue ... to be underused, according to background information in the ...
... may come true; for fat people and inventors. ,Scientists ... those of Britain are no exception. //Currently, two thirds of the ... has decided to put a morbidly obese figure of 2.2 million ... Imperial College London. ,Bloom’s quest is to create a chewing ...
Cached Medicine News:Health News:Tomato and Broccoli Combo may Help Fight Prostate Cancer 2Health News:Amnesia Halts Future Thinking: Study 2Health News:One-time Melanoma Screening Appears to Be Cost-effective for Elderly People 2Health News:Chew That Fat Away 2
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... peripheral nerve stimulator automatically ... nerve locator or a ... upon which patient lead ... NSL-5 electrode lead set, ...
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
... Tupper's Universal Hand Holder and Retractor ... the hand in any position needed. ... skin or tendon hooks, fixate the ... With the patient's hand held firmly, ...
Medicine Products: